BIO’s New CEO, Michelle McMurry-Heath, Aims To ‘Change The Dialogue’ Around Science
Former senior leader in J&J’s medical devices business will take over the reins from Jim Greenwood in June; an immunologist by training, McMurry-Heath brings a resume that is long on scientific, regulatory and corporate experience, but she also has some political qualifications under her belt.
You may also be interested in...
Talks between US FDA and industry to extend the generic drug and prescription drug user fee programs may last into 2021.
Dan Leonard’s communications background, in addition to his policy expertise, may prove useful for the Association for Accessible Medicines as it navigates ongoing market and public policy challenges.
The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.